In pursuit of new anti-angiogenic therapies for cancer treatment

Jun Cai, Song Han, Ruan Qing, Daiqing Liao, Brian Law, Michael E. Boulton

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Despite advances in surgery, radiation therapy, and chemotherapy, patients with cancer have a poor prognosis. Sustained aberrant tumor angiogenesis and metastasis is a major obstacle for effective cancer treatment. Just a few years ago, few would argue that one of the key success stories of the modern cancer medicine were the anti-angiogenic drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway approved by FDA. This initial success inspired many researchers to search for new anti-angiogenic targets and drugs with the hope that one day, anti-angiogenic therapy might really become the panacea for cancer patients. Unfortunately, the limited clinical benefits achieved with anti-angiogenic drugs conflicts with the widely accepted notion that angiogenesis is a key event in tumor progression. Emerging data indicate that unique characteristics of the tumor vasculature within the tumor microenvironment may hold the key for success of antiangiogenic therapy. In particular, the molecular and cellular alterations that sustain aberrant tumor angiogenesis in the face of angiogenic inhibitors represents novel targets for rationally designing and improving current anti-angiogenic strategies.

Original languageEnglish (US)
Pages (from-to)803-814
Number of pages12
JournalFrontiers in Bioscience
Volume16
Issue number3
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Oncology
Tumors
Angiogenesis Inhibitors
Neoplasms
Therapeutics
Chemotherapy
Radiotherapy
Surgery
Vascular Endothelial Growth Factor A
Medicine
Modern 1601-history
Tumor Microenvironment
Drug Delivery Systems
Pharmaceutical Preparations
Research Personnel
Neoplasm Metastasis
Drug Therapy

Keywords

  • Anti-angiogenic Therapy
  • Endothelial cells
  • Review
  • Tumor angiogenesis
  • Vasculature

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Cai, J., Han, S., Qing, R., Liao, D., Law, B., & Boulton, M. E. (2011). In pursuit of new anti-angiogenic therapies for cancer treatment. Frontiers in Bioscience, 16(3), 803-814. https://doi.org/10.2741/3721

In pursuit of new anti-angiogenic therapies for cancer treatment. / Cai, Jun; Han, Song; Qing, Ruan; Liao, Daiqing; Law, Brian; Boulton, Michael E.

In: Frontiers in Bioscience, Vol. 16, No. 3, 01.01.2011, p. 803-814.

Research output: Contribution to journalArticle

Cai, J, Han, S, Qing, R, Liao, D, Law, B & Boulton, ME 2011, 'In pursuit of new anti-angiogenic therapies for cancer treatment', Frontiers in Bioscience, vol. 16, no. 3, pp. 803-814. https://doi.org/10.2741/3721
Cai J, Han S, Qing R, Liao D, Law B, Boulton ME. In pursuit of new anti-angiogenic therapies for cancer treatment. Frontiers in Bioscience. 2011 Jan 1;16(3):803-814. https://doi.org/10.2741/3721
Cai, Jun ; Han, Song ; Qing, Ruan ; Liao, Daiqing ; Law, Brian ; Boulton, Michael E. / In pursuit of new anti-angiogenic therapies for cancer treatment. In: Frontiers in Bioscience. 2011 ; Vol. 16, No. 3. pp. 803-814.
@article{246b8645617e45f2ad74e559a6e11095,
title = "In pursuit of new anti-angiogenic therapies for cancer treatment",
abstract = "Despite advances in surgery, radiation therapy, and chemotherapy, patients with cancer have a poor prognosis. Sustained aberrant tumor angiogenesis and metastasis is a major obstacle for effective cancer treatment. Just a few years ago, few would argue that one of the key success stories of the modern cancer medicine were the anti-angiogenic drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway approved by FDA. This initial success inspired many researchers to search for new anti-angiogenic targets and drugs with the hope that one day, anti-angiogenic therapy might really become the panacea for cancer patients. Unfortunately, the limited clinical benefits achieved with anti-angiogenic drugs conflicts with the widely accepted notion that angiogenesis is a key event in tumor progression. Emerging data indicate that unique characteristics of the tumor vasculature within the tumor microenvironment may hold the key for success of antiangiogenic therapy. In particular, the molecular and cellular alterations that sustain aberrant tumor angiogenesis in the face of angiogenic inhibitors represents novel targets for rationally designing and improving current anti-angiogenic strategies.",
keywords = "Anti-angiogenic Therapy, Endothelial cells, Review, Tumor angiogenesis, Vasculature",
author = "Jun Cai and Song Han and Ruan Qing and Daiqing Liao and Brian Law and Boulton, {Michael E.}",
year = "2011",
month = "1",
day = "1",
doi = "10.2741/3721",
language = "English (US)",
volume = "16",
pages = "803--814",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "3",

}

TY - JOUR

T1 - In pursuit of new anti-angiogenic therapies for cancer treatment

AU - Cai, Jun

AU - Han, Song

AU - Qing, Ruan

AU - Liao, Daiqing

AU - Law, Brian

AU - Boulton, Michael E.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Despite advances in surgery, radiation therapy, and chemotherapy, patients with cancer have a poor prognosis. Sustained aberrant tumor angiogenesis and metastasis is a major obstacle for effective cancer treatment. Just a few years ago, few would argue that one of the key success stories of the modern cancer medicine were the anti-angiogenic drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway approved by FDA. This initial success inspired many researchers to search for new anti-angiogenic targets and drugs with the hope that one day, anti-angiogenic therapy might really become the panacea for cancer patients. Unfortunately, the limited clinical benefits achieved with anti-angiogenic drugs conflicts with the widely accepted notion that angiogenesis is a key event in tumor progression. Emerging data indicate that unique characteristics of the tumor vasculature within the tumor microenvironment may hold the key for success of antiangiogenic therapy. In particular, the molecular and cellular alterations that sustain aberrant tumor angiogenesis in the face of angiogenic inhibitors represents novel targets for rationally designing and improving current anti-angiogenic strategies.

AB - Despite advances in surgery, radiation therapy, and chemotherapy, patients with cancer have a poor prognosis. Sustained aberrant tumor angiogenesis and metastasis is a major obstacle for effective cancer treatment. Just a few years ago, few would argue that one of the key success stories of the modern cancer medicine were the anti-angiogenic drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway approved by FDA. This initial success inspired many researchers to search for new anti-angiogenic targets and drugs with the hope that one day, anti-angiogenic therapy might really become the panacea for cancer patients. Unfortunately, the limited clinical benefits achieved with anti-angiogenic drugs conflicts with the widely accepted notion that angiogenesis is a key event in tumor progression. Emerging data indicate that unique characteristics of the tumor vasculature within the tumor microenvironment may hold the key for success of antiangiogenic therapy. In particular, the molecular and cellular alterations that sustain aberrant tumor angiogenesis in the face of angiogenic inhibitors represents novel targets for rationally designing and improving current anti-angiogenic strategies.

KW - Anti-angiogenic Therapy

KW - Endothelial cells

KW - Review

KW - Tumor angiogenesis

KW - Vasculature

UR - http://www.scopus.com/inward/record.url?scp=79955033414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955033414&partnerID=8YFLogxK

U2 - 10.2741/3721

DO - 10.2741/3721

M3 - Article

C2 - 21196204

AN - SCOPUS:79955033414

VL - 16

SP - 803

EP - 814

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 3

ER -